Although tyrosine kinase inhibitors (TKIs) targeting BCR::ABL1 mutations have improved the therapeutic outcomes in patients with CML,1, 2 resistance to BCR::ABL1 TKI treatment can occur.3 The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.